All In Biotech

Drug Trial Radar · NCT07645651

Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer

Phase 1b Window-of-Opportunity Study Evaluating CDK7 Inhibition in Patients With Localized Basal Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Jul 14, 2027

Study completion Nov 1, 2027

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Lopker Family Foundation; Carrick Therapeutics Limited; The V Foundation for Cancer Research
First posted
Jun 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic cancer.

Conditions

  • Resectable Pancreatic Ductal Adenocarcinoma
  • Borderline Resectable Pancreatic Ductal Adenocarcinoma
  • Locally Advanced Pancreatic Ductal Adenocarcinoma

Interventions

  • SamuraciclibDrug

    Given PO

  • Computed TomographyProcedure

    Undergo CT

  • Endoscopic Ultrasound BiopsyProcedure

    Undergo EUS/FNB

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in ribonucleic acid polymerase II serine levelsTime frame: Within 72 hours post versus pre-samuraciclib treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.